Im Focus Onkologie

, Volume 15, Issue 5, pp 58–65

Moderne adjuvante Chemotherapie und Nachsorge

Kolonkarzinom
  • Volker Heinemann
  • Clemens Gießen
  • Dominik Modest
  • Nicolas Moosmann
  • Sebastian Stintzing
Zertifizierte Fortbildung
  • 9 Downloads

Die Nachsorge beim Kolonkarzinom ist stadienabhängig. Lesen Sie hier, bei welchen Patienten eine adjuvante Chemotherapie sinnvoll ist und wann welche Kontrolluntersuchungen fällig werden.

Literatur

  1. 1.
    Alberts SR al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–1393.PubMedCrossRefGoogle Scholar
  2. 2.
    André T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351.PubMedCrossRefGoogle Scholar
  3. 3.
    André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.PubMedCrossRefGoogle Scholar
  4. 4.
    Biagi JJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011;305(22):2335–2342.PubMedCrossRefGoogle Scholar
  5. 5.
    Desch CE et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005; 23(33):8512–8519.PubMedCrossRefGoogle Scholar
  6. 6.
    Gill S et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–1806.PubMedCrossRefGoogle Scholar
  7. 7.
    Haller DG et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471.PubMedCrossRefGoogle Scholar
  8. 8.
    IMPACT (B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17(5):1356–1363.Google Scholar
  9. 9.
    Jeffery M et al. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;(1):CD002200.PubMedGoogle Scholar
  10. 10.
    Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–2204.PubMedCrossRefGoogle Scholar
  11. 11.
    Locker GY et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327.PubMedCrossRefGoogle Scholar
  12. 12.
    Heinemann V et al. Kolonkarzinom. In: Bruns C (Hrsg.). Manual Gastrointestinale Tumoren (Tumorzentrum München), 8. Auflage, Zuckschwerdt Verlag 2010: 139–185.Google Scholar
  13. 13.
    McCleary et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol. 2009; 27:15 (suppl; abstr 4010).Google Scholar
  14. 14.
    Pfister DG et al. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350(23):2375–2382.PubMedCrossRefGoogle Scholar
  15. 15.
    Quasar Collaborative Group, Gray R et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029.PubMedCrossRefGoogle Scholar
  16. 16.
    Renehan AG et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: Systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813.PubMedCrossRefGoogle Scholar
  17. 17.
    Roth AD et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466–474.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanoff HK et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012;104(3):211–227.PubMedCrossRefGoogle Scholar
  19. 19.
    Sargent DJ et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–1097.PubMedCrossRefGoogle Scholar
  20. 20.
    Sargent DJ et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–8670.PubMedCrossRefGoogle Scholar
  21. 21.
    Sargent D et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877.PubMedCrossRefGoogle Scholar
  22. 22.
    Schmiegel W et al. S3-Leitlinie „Kolorektales Karzinom“ — Aktualisierung 2008 Update S3-Guideline „Colorectal Cancer“ 2008 [Update S3-guideline „colorectal cancer“ 2008]. Z Gastroenterol. 2008; 46(8):799–840.PubMedCrossRefGoogle Scholar
  23. 23.
    Schmoll HJ et al. Phase III trial of capecitabine plus Oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25(1):102–109.PubMedCrossRefGoogle Scholar
  24. 24.
    Schrag D et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20(19):3999–4005.PubMedCrossRefGoogle Scholar
  25. 25.
    Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–2704.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Cutsem EJ, Oliveira J. ESMO Guidelines Working Group. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19 (suppl 2):ii29–30.Google Scholar
  27. 27.
    Wichmann M et al. Results of long-term follow up after curative resection of Dukes A colorectal cancer. World J Surg. 2002;26(6):732–736.PubMedCrossRefGoogle Scholar
  28. 28.
    Wolmark N et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009; 27:18s (suppl; abstr LBA4).Google Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  • Volker Heinemann
    • 1
    • 2
  • Clemens Gießen
    • 1
  • Dominik Modest
    • 1
  • Nicolas Moosmann
    • 1
  • Sebastian Stintzing
    • 1
  1. 1.MünchenDeutschland
  2. 2.Medizinische Klinik und Poliklinik III und Comprehensive Cancer Center LMU Ludwig Maximilians Universität MünchenMünchenDeutschland

Personalised recommendations